{
    "id": "3b0b0981-a681-4c0c-91fb-b662277e92ad",
    "indications": {
        "text": "atzumi indicated acute treatment migraine without aura adults .",
        "doid_entities": [
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            },
            {
                "text": "migraine without aura (DOID:12783)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12783"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "atzumi nasal . ( 2.1 ) recommended dose atzumi 5.2 mg , contents one nasal device , administered one nostril . ( 2.1 ) administer dose , white air pump atzumi device must squeezed three separate times one nostril . ( 2.1 ) dose may repeated , needed , minimum 1 hour first dose . maximum dose 24-hour period 10.4 mg ( two doses atzumi 5.2 mg ) . ( 2.1 ) safety taking 4 doses within 7-day period 12 doses within 30-day period established . ( 2.1 ) prior initiation , cardiovascular evaluation recommended . ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "adverseReactions": "atzumi contraindicated patients : concomitant strong cyp3a4 inhibitors [ ( 5.1 ) ( 7.1 ) ] ischemic heart disease ( e.g . , angina pectoris , history myocardial infarction , documented silent ischemia ) patients symptoms findings consistent coronary artery vasospasm , including prinzmetal 's variant angina [ ( 5.4 ) ] uncontrolled hypertension [ ( 5.5 ) ] peripheral arterial disease sepsis following vascular surgery severe hepatic impairment severe renal impairment known hypersensitivity ergot alkaloids recent ( i.e . , within 24 hours ) 5-ht1 agonists ergotamine-containing ergot-type medications [ ( 7.2 ) ] concomitant peripheral central vasoconstrictors combination may result additive synergistic elevation blood pressure [ ( 5.5 ) ]",
    "ingredients": [
        {
            "name": "DIHYDROERGOTAMINE MESYLATE",
            "code": "81AXN7R2QT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_59756"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        }
    ],
    "organization": "Satsuma Pharmaceuticals, Inc.",
    "name": "ATZUMI",
    "effectiveTime": "20250508",
    "indications_original": "ATZUMI is indicated for the acute treatment of migraine with or without aura in adults.",
    "contraindications_original": "ATZUMI is for nasal administration only. ( 2.1 ) The recommended dose of ATZUMI is 5.2 mg, the contents of one nasal device, administered into one nostril. ( 2.1 ) To administer a dose, the white air pump of the ATZUMI device must be squeezed three separate times into one nostril. ( 2.1 ) The dose may be repeated, if needed, a minimum of 1 hour after the first dose. The maximum dose in a 24-hour period is 10.4 mg (two doses of ATZUMI 5.2 mg). ( 2.1 ) The safety of taking more than 4 doses within a 7-day period or 12 doses within a 30-day period has not been established. ( 2.1 ) Prior to initiation, a cardiovascular evaluation is recommended. ( 2.2 )",
    "adverseReactions_original": "ATZUMI is contraindicated in patients:\n                  \n                     with concomitant use of strong CYP3A4 inhibitors [see Warnings and Precautions (5.1) and Drug Interactions (7.1)]\n                     \n                     with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina [see Warnings and Precautions (5.4)]\n                     \n                     with uncontrolled hypertension [see Warnings and Precautions (5.5)]\n                     \n                     with peripheral arterial disease\n                     with sepsis\n                     following vascular surgery\n                     with severe hepatic impairment\n                     with severe renal impairment\n                     with known hypersensitivity to ergot alkaloids\n                     with recent use (i.e., within 24 hours) of other 5-HT1 agonists or ergotamine-containing or ergot-type medications [see Drug Interactions (7.2)]\n                     \n                     with concomitant use of peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure [see Warnings and Precautions (5.5)]",
    "drug": [
        {
            "name": "ATZUMI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_59756"
        }
    ]
}